; the expected duration of the interruption; and such other information as the Secretary may require. ; and (2) by adding at the end the following: (j) Additional manufacturer reporting for essential drugs and devices Each manufacturer of a drug described in subsection (a) shall provide to the Food and Drug Administration, on an annual basis, or more frequently at the request of the Secretary, information related to the manufacturing capacity of such drug. Such information shall include— (1) details about— (A) all locations of production; (B) the sourcing of all component parts; (C) the sourcing of any active pharmaceutical ingredients; and (D) the use of any scarce or raw materials